First Phase III IBD Trial Reads Out Positive For Janssen’s Tremfya
Data From More Studies Expected Later This Year
The IL-23 inhibitor, entering an increasingly competitive space, posted significant results at Digestive Disease Week from the Phase IIb/III QUASAR induction study in ulcerative colitis.
